This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Psychiatry  • Depression  • Adverse Effects  • Alert me on articles by topic

Bridget M. Kuehn

JAMA. 2007;297:573-574.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Newer generation antidepressants should carry a broader warning of an increased risk of suicidal thoughts and behaviors in not only children and adolescents, but also young adults, recommended a US Food and Drug Administration (FDA) advisory committee after considering new data from the agency. But in an unprecedented step, the panel also recommended that the warnings include information on the benefits of treating depression and the risk of suicide associated with untreated depression, based on emerging data that warnings about potential adverse effects of medications may lead to undertreatment and subsequent suicides.

The committee met December 13 and voted 6 to 2 in favor of extending the existing black box warnings, although members also agreed that the warning should address the benefits of treatment and the risks associated with declining treatment, said Daniel S. Pine, MD, acting chair of the committee and chief of child and adolescent . . . [Full Text of this Article]

AN EMERGING PICTURE

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Late-Life Depression
Unutzer
NEJM 2007;357:2269-2276.
FULL TEXT